Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

Credit: Shutterstock. By the end of the 6th year, Mirena should be removed and replaced if continued use is desired. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...

Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study. This announcement marks a ...

Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

SAN FRANCISCO and DUBLIN, May 6, 2019 /PRNewswire/ -- Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: ...

Low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg and 19.5 mg is associated with a significantly lower risk of first-time depression vs high dose LNG-IUS 52 mg. Overall, 46,565 ...

About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...

First-time users of the long-acting contraceptive levonorgestrel-releasing intrauterine system (LNG-IUS) experience a 15%-23% of reduction in incident depression with the use of low- vs high-dose ...

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ...